痴呆
医学
竞争对手
疾病
帕金森病
美金刚
认知障碍
内科学
认知
加兰他明
神经科学
心理学
认知功能衰退
精神科
多奈哌齐
作者
Per Svenningsson,Eric Westman,Clive Ballard,Dag Aarsland
标识
DOI:10.1016/s1474-4422(12)70152-7
摘要
Dementia is one of the most common and important aspects of Parkinson's disease and has consequences for patients and caregivers, and has health-related costs. Mild cognitive impairment is also common and frequently progresses to dementia. The underlying mechanisms of dementia associated with Parkinson's disease are only partly known and no mechanism-based treatments are available. Both dysmetabolism of α-synuclein and amyloid-protein and cholinergic deficits contribute to cognitive impairment in Parkinson's disease, and preliminary findings show that imaging and neurophysiological and peripheral biomarkers could be useful in diagnosis and prognosis. Rivastigmine is the only licensed treatment for dementia in Parkinson's disease, but emerging evidence suggests that memantine might also be useful. Whether these or other treatments can delay the progression from mild cognitive impairment to dementia in Parkinson's disease is a key research question.
科研通智能强力驱动
Strongly Powered by AbleSci AI